Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Cancer Res ; 27(14): 4036-4053, 2021 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-33771854

RESUMO

PURPOSE: CD40 agonists hold great promise for cancer immunotherapy (CIT) as they enhance dendritic cell (DC) activation and concomitant tumor-specific T-cell priming. However, the broad expression of CD40 accounts for sink and side effects, hampering the efficacy of anti-CD40 antibodies. We hypothesized that these limitations can be overcome by selectively targeting CD40 agonism to the tumor. Therefore, we developed a bispecific FAP-CD40 antibody, which induces CD40 stimulation solely in presence of fibroblast activation protein α (FAP), a protease specifically expressed in the tumor stroma. EXPERIMENTAL DESIGN: FAP-CD40's in vitro activity and FAP specificity were validated by antigen-presenting cell (APC) activation and T-cell priming assays. In addition, FAP-CD40 was tested in subcutaneous MC38-FAP and KPC-4662-huCEA murine tumor models. RESULTS: FAP-CD40 triggered a potent, strictly FAP-dependent CD40 stimulation in vitro. In vivo, FAP-CD40 strongly enhanced T-cell inflammation and growth inhibition of KPC-4662-huCEA tumors. Unlike nontargeted CD40 agonists, FAP-CD40 mediated complete regression of MC38-FAP tumors, entailing long-term protection. A high dose of FAP-CD40 was indispensable for these effects. While nontargeted CD40 agonists induced substantial side effects, highly dosed FAP-CD40 was well tolerated. FAP-CD40 preferentially accumulated in the tumor, inducing predominantly intratumoral immune activation, whereas nontargeted CD40 agonists displayed strong systemic but limited intratumoral effects. CONCLUSIONS: FAP-CD40 abrogates the systemic toxicity associated with nontargeted CD40 agonists. This enables administration of high doses, essential for overcoming CD40 sink effects and inducing antitumor immunity. Consequently, FAP-targeted CD40 agonism represents a promising strategy to exploit the full potential of CD40 signaling for CIT.


Assuntos
Antineoplásicos Imunológicos/administração & dosagem , Antígenos CD40/agonistas , Endopeptidases/efeitos dos fármacos , Imunoterapia/métodos , Proteínas de Membrana/efeitos dos fármacos , Neoplasias/tratamento farmacológico , Animais , Camundongos , Células Tumorais Cultivadas
2.
Postepy Hig Med Dosw (Online) ; 69: 1251-8, 2015 Nov 17.
Artigo em Inglês | MEDLINE | ID: mdl-26671916

RESUMO

Due to the prevalence of lead (Pb) in the environment, the neurotoxic effects on the human body have become an important clinical problem. Despite that Pb concentration in the environment decreased after banning its use in petrol, it is still a significant issue which can affect child development and vision. This paper focuses on the degeneration of the retina under exposure to lead. We present the most frequent sources of exposure to lead in the environment and the influence on vision, mechanisms leading to the apoptosis of photoreceptor cells, as well as strategies for blocking rod apoptosis. We also present Pb-induced disorders in the calcium metabolism of photoreceptor cells and Ca2+-dependent enzymes.


Assuntos
Exposição Ambiental , Intoxicação por Chumbo/complicações , Degeneração Retiniana/etiologia , Apoptose/efeitos dos fármacos , Humanos , Retina/efeitos dos fármacos , Degeneração Retiniana/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...